866-997-4948(US-Canada Toll Free)

Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jun 2015

Category :

Cancer

No. of Pages : 1794 Pages

Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

Summary

Global Markets Directs, Non-Small Cell Lung Cancer - Pipeline Review, H1 2015, provides an overview of the Non-Small Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Non-Small Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 12
Non-Small Cell Lung Cancer Overview 13
Therapeutics Development 14
Non-Small Cell Lung Cancer Therapeutics under Development by Companies 16
Non-Small Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 35
Non-Small Cell Lung Cancer Pipeline Products Glance 39
Non-Small Cell Lung Cancer Products under Development by Companies 43
Non-Small Cell Lung Cancer Products under Investigation by Universities/Institutes 75
Non-Small Cell Lung Cancer Companies Involved in Therapeutics Development 79
Non-Small Cell Lung Cancer Therapeutics Assessment 302
Drug Profiles 344
Non-Small Cell Lung Cancer Recent Pipeline Updates 1194
Non-Small Cell Lung Cancer Dormant Projects 1700
Non-Small Cell Lung Cancer Discontinued Products 1724
Non-Small Cell Lung Cancer Product Development Milestones 1735
Appendix 1744

List of Tables
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2015 63
Number of Products under Development for Non-Small Cell Lung Cancer Comparative Analysis, H1 2015 64
Number of Products under Development by Companies, H1 2015 66
Number of Products under Development by Companies, H1 2015 (Contd..1) 67
Number of Products under Development by Companies, H1 2015 (Contd..2) 68
Number of Products under Development by Companies, H1 2015 (Contd..3) 69
Number of Products under Development by Companies, H1 2015 (Contd..4) 70
Number of Products under Development by Companies, H1 2015 (Contd..5) 71
Number of Products under Development by Companies, H1 2015 (Contd..6) 72
Number of Products under Development by Companies, H1 2015 (Contd..7) 73
Number of Products under Development by Companies, H1 2015 (Contd..8) 74
Number of Products under Development by Companies, H1 2015 (Contd..9) 75
Number of Products under Development by Companies, H1 2015 (Contd..10) 76
Number of Products under Development by Companies, H1 2015 (Contd..11) 77
Number of Products under Development by Companies, H1 2015 (Contd..12) 78
Number of Products under Development by Companies, H1 2015 (Contd..13) 79
Number of Products under Development by Companies, H1 2015 (Contd..14) 80
Number of Products under Development by Companies, H1 2015 (Contd..15) 81
Number of Products under Development by Companies, H1 2015 (Contd..16) 82
Number of Products under Development by Companies, H1 2015 (Contd..17) 83
Number of Products under Investigation by Universities/Institutes, H1 2015 85
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 86
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 87
Comparative Analysis by Late Stage Development, H1 2015 88
Comparative Analysis by Clinical Stage Development, H1 2015 89
Comparative Analysis by Early Stage Development, H1 2015 90
Comparative Analysis by Unknown Stage Development, H1 2015 91
Products under Development by Companies, H1 2015 92
Products under Development by Companies, H1 2015 (Contd..1) 93
Products under Development by Companies, H1 2015 (Contd..2) 94
Products under Development by Companies, H1 2015 (Contd..3) 95
Products under Development by Companies, H1 2015 (Contd..4) 96
Products under Development by Companies, H1 2015 (Contd..5) 97
Products under Development by Companies, H1 2015 (Contd..6) 98
Products under Development by Companies, H1 2015 (Contd..7) 99
Products under Development by Companies, H1 2015 (Contd..8) 100
Products under Development by Companies, H1 2015 (Contd..9) 101
Products under Development by Companies, H1 2015 (Contd..10) 102
Products under Development by Companies, H1 2015 (Contd..11) 103
Products under Development by Companies, H1 2015 (Contd..12) 104
Products under Development by Companies, H1 2015 (Contd..13) 105
Products under Development by Companies, H1 2015 (Contd..14) 106
Products under Development by Companies, H1 2015 (Contd..15) 107
Products under Development by Companies, H1 2015 (Contd..16) 108
Products under Development by Companies, H1 2015 (Contd..17) 109
Products under Development by Companies, H1 2015 (Contd..18) 110
Products under Development by Companies, H1 2015 (Contd..19) 111
Products under Development by Companies, H1 2015 (Contd..20) 112
Products under Development by Companies, H1 2015 (Contd..21) 113
Products under Development by Companies, H1 2015 (Contd..22) 114
Products under Development by Companies, H1 2015 (Contd..23) 115
Products under Development by Companies, H1 2015 (Contd..24) 116
Products under Development by Companies, H1 2015 (Contd..25) 117
Products under Development by Companies, H1 2015 (Contd..26) 118
Products under Development by Companies, H1 2015 (Contd..27) 119
Products under Development by Companies, H1 2015 (Contd..28) 120
Products under Development by Companies, H1 2015 (Contd..29) 121
Products under Development by Companies, H1 2015 (Contd..30) 122
Products under Development by Companies, H1 2015 (Contd..31) 123
Products under Investigation by Universities/Institutes, H1 2015 124
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 125
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 126
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 127
Non-Small Cell Lung Cancer Pipeline by 4SC AG, H1 2015 128
Non-Small Cell Lung Cancer Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 129
Non-Small Cell Lung Cancer Pipeline by AB Science, H1 2015 130
Non-Small Cell Lung Cancer Pipeline by AbbVie Inc., H1 2015 131
Non-Small Cell Lung Cancer Pipeline by ACEA Biosciences, Inc., H1 2015 132
Non-Small Cell Lung Cancer Pipeline by Adaptimmune Limited, H1 2015 133
Non-Small Cell Lung Cancer Pipeline by Advanced Cancer Therapeutics, H1 2015 134
Non-Small Cell Lung Cancer Pipeline by Advenchen Laboratories, LLC, H1 2015 135
Non-Small Cell Lung Cancer Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 136
Non-Small Cell Lung Cancer Pipeline by Allinky Biopharma, H1 2015 137
Non-Small Cell Lung Cancer Pipeline by Altor BioScience Corporation, H1 2015 138
Non-Small Cell Lung Cancer Pipeline by Ambryx Biotechnology, Inc., H1 2015 139
Non-Small Cell Lung Cancer Pipeline by Amgen Inc., H1 2015 140
Non-Small Cell Lung Cancer Pipeline by AndroScience Corporation, H1 2015 141
Non-Small Cell Lung Cancer Pipeline by Arch Biopartners, Inc., H1 2015 142
Non-Small Cell Lung Cancer Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 143
Non-Small Cell Lung Cancer Pipeline by Arog Pharmaceuticals, Inc., H1 2015 144
Non-Small Cell Lung Cancer Pipeline by ArQule, Inc., H1 2015 145
Non-Small Cell Lung Cancer Pipeline by Array BioPharma Inc., H1 2015 146
Non-Small Cell Lung Cancer Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 147
Non-Small Cell Lung Cancer Pipeline by Ascenta Therapeutics, Inc., H1 2015 148
Non-Small Cell Lung Cancer Pipeline by Astellas Pharma Inc., H1 2015 149
Non-Small Cell Lung Cancer Pipeline by Astex Pharmaceuticals, Inc., H1 2015 150
Non-Small Cell Lung Cancer Pipeline by AstraZeneca Plc, H1 2015 151
Non-Small Cell Lung Cancer Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 152
Non-Small Cell Lung Cancer Pipeline by Axelar AB, H1 2015 153
Non-Small Cell Lung Cancer Pipeline by Azaya Therapeutics Incorporated, H1 2015 154
Non-Small Cell Lung Cancer Pipeline by Basilea Pharmaceutica AG, H1 2015 155
Non-Small Cell Lung Cancer Pipeline by Bayer AG, H1 2015 156
Non-Small Cell Lung Cancer Pipeline by Benitec Biopharma Limited, H1 2015 157
Non-Small Cell Lung Cancer Pipeline by BerGenBio AS, H1 2015 158
Non-Small Cell Lung Cancer Pipeline by Beta Pharma, Inc., H1 2015 159
Non-Small Cell Lung Cancer Pipeline by BIND Therapeutics, Inc., H1 2015 160
Non-Small Cell Lung Cancer Pipeline by BIOCAD, H1 2015 161
Non-Small Cell Lung Cancer Pipeline by BioCancell Ltd, H1 2015 162
Non-Small Cell Lung Cancer Pipeline by BioLineRx, Ltd., H1 2015 163
Non-Small Cell Lung Cancer Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015 164
Non-Small Cell Lung Cancer Pipeline by Biothera, Inc., H1 2015 165
Non-Small Cell Lung Cancer Pipeline by Boehringer Ingelheim GmbH, H1 2015 166
Non-Small Cell Lung Cancer Pipeline by Boston Biomedical, Inc., H1 2015 167
Non-Small Cell Lung Cancer Pipeline by Bristol-Myers Squibb Company, H1 2015 168
Non-Small Cell Lung Cancer Pipeline by Calithera Biosciences, Inc., H1 2015 169
Non-Small Cell Lung Cancer Pipeline by CanBas Co., Ltd., H1 2015 170
Non-Small Cell Lung Cancer Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 171
Non-Small Cell Lung Cancer Pipeline by CASI Pharmaceuticals Inc., H1 2015 172
Non-Small Cell Lung Cancer Pipeline by cCAM Biotherapeutics Ltd., H1 2015 173
Non-Small Cell Lung Cancer Pipeline by Celgene Corporation, H1 2015 174
Non-Small Cell Lung Cancer Pipeline by CellAct Pharma GmbH, H1 2015 175
Non-Small Cell Lung Cancer Pipeline by Celldex Therapeutics, Inc., H1 2015 176
Non-Small Cell Lung Cancer Pipeline by Cellectar Biosciences, Inc., H1 2015 177
Non-Small Cell Lung Cancer Pipeline by Cellectis S.A., H1 2015 178
Non-Small Cell Lung Cancer Pipeline by Cellmid Limited, H1 2015 179
Non-Small Cell Lung Cancer Pipeline by Celltrion, Inc., H1 2015 180
Non-Small Cell Lung Cancer Pipeline by Cellular Biomedicine Group, Inc., H1 2015 181
Non-Small Cell Lung Cancer Pipeline by Centrose Llc, H1 2015 182
Non-Small Cell Lung Cancer Pipeline by Chipscreen Biosciences Ltd, H1 2015 183
Non-Small Cell Lung Cancer Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 184
Non-Small Cell Lung Cancer Pipeline by Clovis Oncology, Inc., H1 2015 185
Non-Small Cell Lung Cancer Pipeline by Conkwest, Inc., H1 2015 186
Non-Small Cell Lung Cancer Pipeline by Corcept Therapeutics Incorporated, H1 2015 187
Non-Small Cell Lung Cancer Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 188
Non-Small Cell Lung Cancer Pipeline by Critical Outcome Technologies Inc., H1 2015 189
Non-Small Cell Lung Cancer Pipeline by CTI BioPharma Corp., H1 2015 190
Non-Small Cell Lung Cancer Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 191
Non-Small Cell Lung Cancer Pipeline by CureVac GmbH, H1 2015 192
Non-Small Cell Lung Cancer Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 193
Non-Small Cell Lung Cancer Pipeline by Daiichi Sankyo Company, Limited, H1 2015 194
Non-Small Cell Lung Cancer Pipeline by DanDrit Biotech A/S, H1 2015 195
Non-Small Cell Lung Cancer Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 196
Non-Small Cell Lung Cancer Pipeline by DEKK-TEC, Inc., H1 2015 197
Non-Small Cell Lung Cancer Pipeline by DiNonA Inc., H1 2015 198
Non-Small Cell Lung Cancer Pipeline by Domainex Limited, H1 2015 199
Non-Small Cell Lung Cancer Pipeline by DormaTarg, Inc., H1 2015 200
Non-Small Cell Lung Cancer Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 201
Non-Small Cell Lung Cancer Pipeline by Eisai Co., Ltd., H1 2015 202
Non-Small Cell Lung Cancer Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 203
Non-Small Cell Lung Cancer Pipeline by Eli Lilly and Company, H1 2015 204
Non-Small Cell Lung Cancer Pipeline by Endocyte, Inc., H1 2015 205
Non-Small Cell Lung Cancer Pipeline by EnGeneIC Ltd, H1 2015 206
Non-Small Cell Lung Cancer Pipeline by EntreChem, S.L., H1 2015 207
Non-Small Cell Lung Cancer Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 208
Non-Small Cell Lung Cancer Pipeline by Eudendron S.r.l., H1 2015 209
Non-Small Cell Lung Cancer Pipeline by Exelixis, Inc., H1 2015 210
Non-Small Cell Lung Cancer Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 211
Non-Small Cell Lung Cancer Pipeline by Five Prime Therapeutics, Inc., H1 2015 212
Non-Small Cell Lung Cancer Pipeline by Fortress Biotech, Inc., H1 2015 213
Non-Small Cell Lung Cancer Pipeline by Ganymed Pharmaceuticals AG, H1 2015 214
Non-Small Cell Lung Cancer Pipeline by GeneFrontier Corporation, H1 2015 215
Non-Small Cell Lung Cancer Pipeline by Genelux Corporation, H1 2015 216
Non-Small Cell Lung Cancer Pipeline by Genentech, Inc., H1 2015 217
Non-Small Cell Lung Cancer Pipeline by Genmab A/S, H1 2015 218
Non-Small Cell Lung Cancer Pipeline by Genor BioPharma Co., Ltd., H1 2015 219
Non-Small Cell Lung Cancer Pipeline by Genosco, H1 2015 220
Non-Small Cell Lung Cancer Pipeline by Gilead Sciences, Inc., H1 2015 221
Non-Small Cell Lung Cancer Pipeline by GlaxoSmithKline Plc, H1 2015 222
Non-Small Cell Lung Cancer Pipeline by Globeimmune, Inc., H1 2015 223
Non-Small Cell Lung Cancer Pipeline by GlycaNova Norway AS, H1 2015 224
Non-Small Cell Lung Cancer Pipeline by Glycotope GmbH, H1 2015 225
Non-Small Cell Lung Cancer Pipeline by Golden Biotechnology Corp., H1 2015 226
Non-Small Cell Lung Cancer Pipeline by Halozyme Therapeutics, Inc., H1 2015 227
Non-Small Cell Lung Cancer Pipeline by HanAll Biopharma Co., Ltd., H1 2015 228
Non-Small Cell Lung Cancer Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 229
Non-Small Cell Lung Cancer Pipeline by Heat Biologics, Inc., H1 2015 230
Non-Small Cell Lung Cancer Pipeline by HEC Pharm Co., Ltd., H1 2015 231
Non-Small Cell Lung Cancer Pipeline by Helix BioPharma Corp., H1 2015 232
Non-Small Cell Lung Cancer Pipeline by Hospira, Inc., H1 2015 233
Non-Small Cell Lung Cancer Pipeline by Humanetics Corporation, H1 2015 234
Non-Small Cell Lung Cancer Pipeline by Hutchison MediPharma Limited, H1 2015 235
Non-Small Cell Lung Cancer Pipeline by Ignyta, Inc., H1 2015 236
Non-Small Cell Lung Cancer Pipeline by Immune Design Corp., H1 2015 237
Non-Small Cell Lung Cancer Pipeline by Immune Pharmaceuticals Inc., H1 2015 238
Non-Small Cell Lung Cancer Pipeline by ImmunGene, Inc., H1 2015 239
Non-Small Cell Lung Cancer Pipeline by ImmunoFrontier, Inc., H1 2015 240
Non-Small Cell Lung Cancer Pipeline by ImmunoGen, Inc., H1 2015 241
Non-Small Cell Lung Cancer Pipeline by Immunome Inc., H1 2015 242
Non-Small Cell Lung Cancer Pipeline by Immunomedics, Inc., H1 2015 243
Non-Small Cell Lung Cancer Pipeline by Incanthera Ltd., H1 2015 244
Non-Small Cell Lung Cancer Pipeline by Incuron, LLC, H1 2015 245
Non-Small Cell Lung Cancer Pipeline by Incyte Corporation, H1 2015 246
Non-Small Cell Lung Cancer Pipeline by Intezyne, Inc, H1 2015 247
Non-Small Cell Lung Cancer Pipeline by Io Therapeutics, Inc., H1 2015 248
Non-Small Cell Lung Cancer Pipeline by Isis Pharmaceuticals, Inc., H1 2015 249
Non-Small Cell Lung Cancer Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 250
Non-Small Cell Lung Cancer Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 251
Non-Small Cell Lung Cancer Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2015 252
Non-Small Cell Lung Cancer Pipeline by Johnson & Johnson, H1 2015 253
Non-Small Cell Lung Cancer Pipeline by Juno Therapeutics Inc., H1 2015 254
Non-Small Cell Lung Cancer Pipeline by Kadmon Corporation, LLC, H1 2015 255
Non-Small Cell Lung Cancer Pipeline by KAEL-GemVax Co., Ltd., H1 2015 256
Non-Small Cell Lung Cancer Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 257
Non-Small Cell Lung Cancer Pipeline by Loxo Oncology, Inc., H1 2015 258
Non-Small Cell Lung Cancer Pipeline by Mabion SA, H1 2015 259
Non-Small Cell Lung Cancer Pipeline by MacroGenics, Inc., H1 2015 260
Non-Small Cell Lung Cancer Pipeline by Mebiopharm Co., Ltd., H1 2015 261
Non-Small Cell Lung Cancer Pipeline by MedImmune, LLC, H1 2015 262
Non-Small Cell Lung Cancer Pipeline by Merck & Co., Inc., H1 2015 263
Non-Small Cell Lung Cancer Pipeline by Merck KGaA, H1 2015 264
Non-Small Cell Lung Cancer Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 265
Non-Small Cell Lung Cancer Pipeline by Mersana Therapeutics, Inc., H1 2015 266
Non-Small Cell Lung Cancer Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 267
Non-Small Cell Lung Cancer Pipeline by Mirati Therapeutics Inc., H1 2015 268
Non-Small Cell Lung Cancer Pipeline by Mirna Therapeutics, Inc., H1 2015 269
Non-Small Cell Lung Cancer Pipeline by MolMed S.p.A., H1 2015 270
Non-Small Cell Lung Cancer Pipeline by Morphotek, Inc., H1 2015 271
Non-Small Cell Lung Cancer Pipeline by NanoCarrier Co., Ltd., H1 2015 272
Non-Small Cell Lung Cancer Pipeline by Natco Pharma Limited, H1 2015 273
Non-Small Cell Lung Cancer Pipeline by Nektar Therapeutics, H1 2015 274
Non-Small Cell Lung Cancer Pipeline by NeoPharm Co., Ltd., H1 2015 275
Non-Small Cell Lung Cancer Pipeline by NewLink Genetics Corporation, H1 2015 276
Non-Small Cell Lung Cancer Pipeline by Nimbus Therapeutics, LLC, H1 2015 277
Non-Small Cell Lung Cancer Pipeline by Novartis AG, H1 2015 278
Non-Small Cell Lung Cancer Pipeline by NuCana BioMed Limited, H1 2015 279

List of Figures
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2015 63
Number of Products under Development for Non-Small Cell Lung Cancer Comparative Analysis, H1 2015 64
Number of Products under Development by Companies, H1 2015 65
Number of Products under Investigation by Universities/Institutes, H1 2015 84
Comparative Analysis by Late Stage Development, H1 2015 88
Comparative Analysis by Clinical Stage Development, H1 2015 89
Comparative Analysis by Early Stage Products, H1 2015 90
Assessment by Monotherapy Products, H1 2015 351
Assessment by Combination Products, H1 2015 352
Number of Products by Top 10 Targets, H1 2015 353
Number of Products by Stage and Top 10 Targets, H1 2015 353
Number of Products by Top 10 Mechanism of Actions, H1 2015 375
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 375
Number of Products by Top 10 Routes of Administration, H1 2015 389
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 389
Number of Products by Top 10 Molecule Types, H1 2015 391
Number of Products by Stage and Top 10 Molecule Types, H1 2015 391

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *